9,830 Shares in BridgeBio Pharma, Inc. $BBIO Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,830 shares of the company’s stock, valued at approximately $424,000.

A number of other institutional investors also recently bought and sold shares of the stock. KLP Kapitalforvaltning AS lifted its position in BridgeBio Pharma by 20.1% in the second quarter. KLP Kapitalforvaltning AS now owns 28,035 shares of the company’s stock worth $1,211,000 after buying an additional 4,700 shares during the last quarter. DAVENPORT & Co LLC bought a new stake in shares of BridgeBio Pharma during the second quarter worth $207,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of BridgeBio Pharma by 15.3% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,335 shares of the company’s stock worth $317,000 after purchasing an additional 971 shares during the last quarter. Platinum Investment Management Ltd. lifted its position in shares of BridgeBio Pharma by 7.6% during the second quarter. Platinum Investment Management Ltd. now owns 75,708 shares of the company’s stock worth $3,269,000 after purchasing an additional 5,358 shares during the last quarter. Finally, PFG Investments LLC bought a new stake in shares of BridgeBio Pharma during the second quarter worth $255,000. 99.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Andrea Ellis sold 17,167 shares of BridgeBio Pharma stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $49.00, for a total value of $841,183.00. Following the transaction, the director owned 18,589 shares in the company, valued at $910,861. The trade was a 48.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $54.78, for a total value of $2,191,200.00. Following the completion of the transaction, the chief executive officer owned 855,686 shares in the company, valued at $46,874,479.08. This trade represents a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 597,913 shares of company stock valued at $29,034,227 over the last three months. Corporate insiders own 18.20% of the company’s stock.

BridgeBio Pharma Trading Up 1.0%

Shares of BridgeBio Pharma stock opened at $56.50 on Wednesday. The firm has a market cap of $10.80 billion, a P/E ratio of -13.81 and a beta of 1.36. BridgeBio Pharma, Inc. has a 12 month low of $21.72 and a 12 month high of $57.47. The stock’s fifty day moving average price is $51.40 and its 200-day moving average price is $43.22.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $110.57 million during the quarter, compared to analysts’ expectations of $98.46 million. The company’s revenue for the quarter was up 4999.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.39) EPS. Analysts forecast that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BBIO. Scotiabank lifted their target price on BridgeBio Pharma from $55.00 to $57.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, August 6th. Bank of America lifted their target price on BridgeBio Pharma from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Wednesday, June 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Pharma in a research report on Wednesday, October 8th. Truist Financial began coverage on BridgeBio Pharma in a research report on Monday, July 21st. They set a “buy” rating and a $66.00 target price for the company. Finally, Oppenheimer lifted their target price on BridgeBio Pharma from $60.00 to $61.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 6th. Seventeen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $63.94.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.